Storage and distribution

Storage and distribution
Product Description

Lonza Biologics Inc offers wide range of pharma products and services which includes storage and distribution. It belongs to cell therapy products and services category. It is is equipped with redundant automated monitoring systems to ensure the safety and security of all stored MCBs and products.

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since

More Products from Lonza Capsules & Health Ingredients (52)

  • Service plan options for readers and pyrotec™

    Product Service plan options for readers and pyrotec™

    Lonza Biologics Inc offers wide range of pharma products and services which includes service plan options for readers and pyrotec™. It belongs to pharma & biotech complementary business solutions services and products category. It includes elx808™ absorbance plate reader, flx800™ fluorescenc...
  • Skeletal muscle cell growth media

    Product Skeletal muscle cell growth media

    Lonza Biologics Inc offers wide range of pharma products and services which includes Lonza Biologics Inc offers wide range of pharma products and services which includes . It belongs to primary and adult stem cells, human primary cells and media, skeletal muscle cells & media. It offers two varieties of S...
  • William's medium e, without l-glutamine

    Product William's medium e, without l-glutamine

    Lonza Biologics Inc offers wide range of pharma products and services which includes william's medium e, without l-glutamine. It belongs to cell culture products, classical media, other media products category. It is used as a reduced serum-supplemented medium with enriched amino acids and double the glu...
  • Solution

    Product Solution

    Lonza Biologics Inc offers wide range of pharma products and services which includes solutionLonza Biologics Inc offers wide range of pharma products and services which includes solution. It belongs to pharma & biotech, informatics moda™ , paperless qc micro solution services and products category. I...
  • Stem cells media

    Product Stem cells media

    Lonza Biologics Inc offers wide range of pharma products and services which includes stem cells media. It belongs to upstream serum-free media and feed formulations services and products category. Contact us for more information.
  • Sterilization services

    Product Sterilization services

    Lonza Biologics Inc offers wide range of pharma products and services which includes sterilization services. It belongs to pharma & biotech complementary business solutions services and products category. It allow the flexibility of handling almost any size load or packaging configuration used in the medic...
  • TC 100 Insect Medium with L-glutamine

    Product TC 100 Insect Medium with L-glutamine

    Lonza Biologics Inc offers wide range of pharma products and services which includes tc 100 insect medium with l-glutamine. It belongs to cell culture products, classical media, insect media services and products category. Contact us for more information.
  • Unprocessed human bone marrow

    Product Unprocessed human bone marrow

    Lonza Biologics Inc offers wide range of pharma products and services which includes unprocessed human bone marrow. It belongs to primary and adult stem cells adult stem cells & media services & products category. Contact us for more information.
  • Validation package

    Product Validation package

    Lonza Biologics Inc offers wide range of pharma products and services which includes validation package. It belongs to downstream products and services category. It comprehensive package represents multiple analysis conducted by Lonza Biologics Inc, along with the support of qualified vendors, to determine...
  • Solid Form Services

    Product Solid Form Services

    The selection of a lead solid form of an API is a critical step in early pharmaceutical development. Determining the most suitable chemical and physical form impacts a range of critical parameters including manufacturability, stability and bioavailability. The selection of a lead solid involves the screeni...
  • Winkqcl™ endotoxin detection & analysis software

    Product Winkqcl™ endotoxin detection & analysis software

    Lonza Biologics Inc offers wide range of pharma products and services which includes winkqcl™ endotoxin detection & analysis software. It belongs to pharma & biotech informatics services and products category. Features: integration of molecular devices® spectramax®, gemini™ and versamax™ r...
  • Active Pharmaceutical Ingredients and Intermediates

    Product Active Pharmaceutical Ingredients and Intermediates

    We provide customized chemical synthesis for active pharmaceutical ingredients from concept to commercial supply.

    We are an industry-leading integrated development and manufacturing service provider for small molecule drug substances and their intermediates.

    Chemistry is c...

Lonza Capsules & Health Ingredients resources (6)

  • News CPHI North America 2023 – From the Floor

    Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 
  • Video Lonza

    Enabling a healthier world.
  • News Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing

    The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies
  • Video Making a Splash in the US Market: How PBPK Modeling is Playing a Central Role in Risk Reduction in Early Drug Development

    Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.
  • News Lonza Switzerland site to undergo expansion of microbial development capabilities

    The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects
  • News Lonza boosts exosome capability with Codiak BioSciences facility acquisition

    The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies